Mr David ChildsDirector of Product Supply and Commerical Alliances
Dr Mark SampsonChief Medical Officer
Therakind is a private European pharmaceutical company with the primary objective of increasing the availability of authorised speciality medicines and ensuring that these medicines are both safe and effective.
Therakind creates, develops, and improves paediatric and other speciality medicinal products and has already successfully brought two paediatric medicines and a further speciality medicine to market. An extensive pipeline of products is under development.
Dr Susan ConroyCEO
XenoGesis Ltd. is a laboratory-based contract research organisation (CRO) specialised in preclinical drug metabolism & pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation. The core XenoGesis team has an enviable track record of delivery in drug discovery.
It is clear that identifying poor compounds early through scientific rigor is key in preventing progression into more expensive pre-clinical tests. Even a minor improvement in early-stage drug failure prediction will result in significant time and cost savings for R&D companies. Specifically,XenoGesis can identify the potential 'winners' and 'losers' in a selection of compounds synthesised in drug discovery campaigns. Moreover, providing iterative feedback to the research team based on the results and recommending next steps is a key focus for XenoGesis.